Physician profile
Hon C Chan
NPI 1669420741
$2,994.22
in general payments reported to CMS, 2019-2025
14 companies · $39.73 in 2025
The $39.73 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $204 · 2021: $586 · 2022: $599 · 2023: $734 · 2024: $157 · 2025: $39.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $600.57 | 2019-2024 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $574.44 | 2019-2023 | Fanapt, Hetlioz |
| Lundbeck LLC | $438.98 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $337.24 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.88 | 2020-2025 | Caplyta |
| Alkermes, INC. | $241.73 | 2019-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $131.50 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $126.47 | 2019-2023 | Uzedy |
| Sunovion Pharmaceuticals INC. | $115.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $76.76 | 2019-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $51.98 | 2022-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $17.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.52 | 2022 | |
| Noven Therapeutics, LLC | $14.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hon Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.